Stockscreener 앱 받기
104.44
0.47%
0.4841
전일 마감가:
$103.95
열려 있는:
$104.38
하루 거래량:
553.90K
Relative Volume:
0.65
시가총액:
$25.15B
수익:
$3.13B
순이익/손실:
$-381.72M
주가수익비율:
-65.21
EPS:
-1.6017
순현금흐름:
$-2.15B
1주 성능:
-0.56%
1개월 성능:
-1.00%
6개월 성능:
-0.48%
1년 성능:
-4.16%
1일 변동 폭
$102.59
$105.03
1주일 범위
$101.66
$109.02
52주 변동 폭
$81.20
$129.27
바이오앤테크 Stock (BNTX) Company Profile
BNTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
104.60 | 25.00B | 3.13B | -381.72M | -2.15B | -1.6017 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.80 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.02 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.55 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
836.27 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.19 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
바이오앤테크 Stock (BNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 재확인 | H.C. Wainwright | Buy |
| 2025-05-29 | 개시 | Goldman | Neutral |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-01-10 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 재확인 | BMO Capital Markets | Outperform |
| 2024-11-19 | 개시 | Berenberg | Buy |
| 2024-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-09-24 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-08-02 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-14 | 개시 | Evercore ISI | In-line |
| 2024-02-23 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-05 | 개시 | Oppenheimer | Perform |
| 2023-12-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-10-16 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-17 | 업그레이드 | Redburn | Neutral → Buy |
| 2022-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-08-17 | 개시 | Cowen | Market Perform |
| 2022-07-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2021-12-16 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-08-11 | 업그레이드 | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-16 | 다운그레이드 | Redburn | Neutral → Sell |
| 2021-05-18 | 개시 | Goldman | Neutral |
| 2021-05-11 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-08-03 | 재개 | Berenberg | Buy |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-06-30 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 개시 | H.C. Wainwright | Neutral |
| 2020-01-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-11-05 | 개시 | Wolfe Research | Outperform |
| 2019-11-04 | 개시 | Berenberg | Buy |
| 2019-11-04 | 개시 | BofA/Merrill | Buy |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-11-04 | 개시 | JP Morgan | Overweight |
| 2019-11-04 | 개시 | SVB Leerink | Outperform |
| 2019-11-04 | 개시 | UBS | Buy |
모두보기
바이오앤테크 주식(BNTX)의 최신 뉴스
BioNTech SE Reports Q3 2025 Financial Results - TipRanks
BioNTech’s Promising Clinical Study: A New Hope for Advanced Solid Tumors? - MSN
BioNTech SE’s Promising Phase 3 Study on NSCLC Treatment: A Potential Game-Changer - TipRanks
BioNTech’s BNT327: A Promising New Approach in Breast Cancer Treatment - MSN
BioNTech’s BNT116 Study: A New Hope for Advanced Lung Cancer? - MSN
BioNTech’s Promising PDAC Study: Market Implications and Progress - MSN
BioNTech’s Latest Clinical Study: A New Hope for Advanced Solid Tumors? - TipRanks
ETFs Investing in BioNTech SE Sponsored ADR Stocks - TradingView
BioNTech’s Latest Study on BNT327: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment - TipRanks
Bristol-Myers Squibb and BioNTech’s New Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Bristol-Myers Squibb and BioNTech Launch New Colorectal Cancer Study - TipRanks
BioNTech’s Promising Study on BNT113 and Pembrolizumab for Head and Neck Cancer - TipRanks
Pfizer and BioNTech’s New Shingles Vaccine Study: A Potential Game Changer - TipRanks
BioNTech’s Promising Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks
BioNTech’s Promising Phase 1/2a Trial: A New Hope for Advanced Solid Tumors - TipRanks
BioNTech’s Promising Phase II Study on MIUC: A Potential Game-Changer? - TipRanks
BioNTech’s BNT326 Study: A New Hope for Advanced Tumor Treatment? - TipRanks
Bristol-Myers Squibb and BioNTech SE Launch New Study on Pumitamig for Triple-Negative Breast Cancer - TipRanks
Pfizer and BioNTech’s New Study on Variant-Adapted COVID-19 Vaccine for Children: What Investors Need to Know - TipRanks
BioNTech SE’s Promising Phase II Study on Advanced Solid Tumors - TipRanks
BioNTech SE’s New Study on PM8002: A Potential Game-Changer in Colorectal Cancer Treatment - TipRanks
Pfizer and BioNTech’s New Vaccine Study: A Potential Game-Changer for COVID-19 Prevention - TipRanks
BioNTech’s Latest Clinical Trial: A Potential Game-Changer in Breast Cancer Treatment? - TipRanks
BioNTech’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks
Pfizer and BioNTech’s Innovative Vaccine Study: A Potential Game-Changer? - TipRanks
Human Combinatorial Antibody Libraries Market to Surge USD 189.57 Million by 2034, Reports Towards Healthcare - GlobeNewswire Inc.
Sector Gamma AS Grows Stake in BioNTech SE Sponsored ADR $BNTX - MarketBeat
DekaBank Deutsche Girozentrale Grows Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech Clears Major Hurdle in CureVac Acquisition Process () - aktiencheck.de
Allianz Asset Management GmbH Acquires 2,815 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
BioNTech Clears Final Hurdle for $1.25 Billion CureVac Acquisition () - aktiencheck.de
Aberdeen Group plc Grows Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Mirae Asset Global Investments Co. Ltd. Purchases 533 Shares of BioNTech SE Sponsored ADR $BNTX - Defense World
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - The Globe and Mail
Shell Asset Management Co. Buys 5,398 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR $BNTX Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Slow Capital Inc. Sells 3,415 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency? - The Globe and Mail
Why BioNTech Stock Jumped by Nearly 4% on Wednesday - The Globe and Mail
TB Alternative Assets Ltd. Trims Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
JPMorgan Chase & Co. Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock Price - Defense World
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Baader Bank Aktiengesellschaft Acquires 9,040 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
바이오앤테크 (BNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.99%
0.29%
자본화:
|
볼륨(24시간):